134 related articles for article (PubMed ID: 28395195)
1. Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin.
Zhang Y; Zhang Z; Gou Y; Jiang M; Khan H; Zhou Z; Liang H; Yang F
J Inorg Biochem; 2017 Jul; 172():1-8. PubMed ID: 28395195
[TBL] [Abstract][Full Text] [Related]
2. Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer.
Gou Y; Zhang Y; Qi J; Chen S; Zhou Z; Wu X; Liang H; Yang F
Oncotarget; 2016 Oct; 7(41):67004-67019. PubMed ID: 27564255
[TBL] [Abstract][Full Text] [Related]
3. Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier.
Gou Y; Zhang Y; Zhang Z; Wang J; Zhou Z; Liang H; Yang F
Mol Pharm; 2017 Jun; 14(6):1861-1873. PubMed ID: 28471669
[TBL] [Abstract][Full Text] [Related]
4. Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain.
Qi J; Zhang Y; Gou Y; Zhang Z; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2016 May; 13(5):1501-7. PubMed ID: 27017838
[TBL] [Abstract][Full Text] [Related]
5. Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain.
Gou Y; Qi J; Ajayi JP; Zhang Y; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2015 Oct; 12(10):3597-609. PubMed ID: 26354410
[TBL] [Abstract][Full Text] [Related]
6. Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin.
Wang J; Gou Y; Zhang Z; Yu P; Qi J; Qin Q; Sun H; Wu X; Liang H; Yang F
Mol Pharm; 2018 Jun; 15(6):2180-2193. PubMed ID: 29722993
[TBL] [Abstract][Full Text] [Related]
7. Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain.
Qi J; Gou Y; Zhang Y; Yang K; Chen S; Liu L; Wu X; Wang T; Zhang W; Yang F
J Med Chem; 2016 Aug; 59(16):7497-511. PubMed ID: 27441502
[TBL] [Abstract][Full Text] [Related]
8. Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin.
Gou Y; Zhang Z; Qi J; Liang S; Zhou Z; Yang F; Liang H
J Inorg Biochem; 2015 Dec; 153():13-22. PubMed ID: 26398432
[TBL] [Abstract][Full Text] [Related]
9. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin.
Zhang Y; Ho A; Yue J; Kong L; Zhou Z; Wu X; Yang F; Liang H
Eur J Med Chem; 2014 Oct; 86():449-55. PubMed ID: 25200980
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the copper(II) complexes cytotoxicity to cancer cells through bound to human serum albumin.
Gou Y; Zhang Y; Qi J; Zhou Z; Yang F; Liang H
J Inorg Biochem; 2015 Mar; 144():47-55. PubMed ID: 25573806
[TBL] [Abstract][Full Text] [Related]
11. Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate.
Zhang Z; Yu P; Gou Y; Zhang J; Li S; Cai M; Sun H; Yang F; Liang H
J Med Chem; 2019 Dec; 62(23):10630-10644. PubMed ID: 31693353
[TBL] [Abstract][Full Text] [Related]
12. HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach.
Yang F; Liang H
Future Med Chem; 2016; 8(2):89-91. PubMed ID: 26824398
[No Abstract] [Full Text] [Related]
13. Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents.
Qi J; Zhang Y; Gou Y; Lee P; Wang J; Chen S; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2016 Sep; 13(9):3098-105. PubMed ID: 27453125
[TBL] [Abstract][Full Text] [Related]
14. Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin-Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor Microenvironment.
Man X; Li S; Xu G; Li W; Zhu M; Zhang Z; Liang H; Yang F
J Med Chem; 2024 Apr; 67(7):5744-5757. PubMed ID: 38553427
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Evaluation of Benzimidazole-Derived Biocompatible Copper(II) and Zinc(II) Complexes as Anticancer Chemotherapeutics.
AlAjmi MF; Hussain A; Rehman MT; Khan AA; Shaikh PA; Khan RA
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772746
[TBL] [Abstract][Full Text] [Related]
16. Binding and Anticancer Properties of Plumbagin with Human Serum Albumin.
Gou Y; Zhang Y; Qi J; Kong L; Zhou Z; Liang S; Yang F; Liang H
Chem Biol Drug Des; 2015 Sep; 86(3):362-9. PubMed ID: 25534036
[TBL] [Abstract][Full Text] [Related]
17. Developing a Multitargeted Anticancer Palladium(II) Agent Based on the His-242 Residue in the IIA Subdomain of Human Serum Albumin.
Li W; Li S; Zhang Z; Xu G; Man X; Yang F; Liang H
J Med Chem; 2023 Jul; 66(13):8564-8579. PubMed ID: 37321208
[TBL] [Abstract][Full Text] [Related]
18. Mixed-ligand copper(ii) Schiff base complexes: the role of the co-ligand in DNA binding, DNA cleavage, protein binding and cytotoxicity.
Lian WJ; Wang XT; Xie CZ; Tian H; Song XQ; Pan HT; Qiao X; Xu JY
Dalton Trans; 2016 May; 45(22):9073-87. PubMed ID: 27163172
[TBL] [Abstract][Full Text] [Related]
19. Exploring the copper(II)-aminotriazole complex-binding sites of human serum albumin.
Yang L; He L; Zhang J; An S; Zhang L
J Biol Inorg Chem; 2015 Sep; 20(6):1059-68. PubMed ID: 26239697
[TBL] [Abstract][Full Text] [Related]
20. A novel water-soluble Cu(II) gluconate complex inhibits cancer cell growth by triggering apoptosis and ferroptosis related mechanisms.
Cai DH; Liang BF; Chen BH; Liu QY; Pan ZY; Le XY; He L
J Inorg Biochem; 2023 Sep; 246():112299. PubMed ID: 37354603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
